Clinical data | |
---|---|
Pronunciation | /aɪˈfɒsfəmaɪd/ |
Trade names | Ifex, others |
Other names | 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide |
AHFS/Drugs.com | Monograph |
MedlinePlus | a695023 |
Pregnancy category |
|
Routes of administration | intravenously |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 100% |
Metabolism | Hepatic |
Elimination half-life | 60–80% in 72 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.021.126 |
Chemical and physical data | |
Formula | C7H15Cl2N2O2P |
Molar mass | 261.08 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Ifosfamide (IFO), sold under the brand name Ifex among others, is a chemotherapy medication used to treat a number of types of cancer.[2] This includes testicular cancer, soft tissue sarcoma, osteosarcoma, bladder cancer, small cell lung cancer, cervical cancer, and ovarian cancer.[2] It is administered by injection into a vein.[2]
Common side effects include hair loss, vomiting, blood in the urine, infections, and kidney problems.[2] Other severe side effects include bone marrow suppression and decreased level of consciousness.[2] Use during pregnancy will likely result in harm to the baby.[2] Ifosfamide is in the alkylating agent and nitrogen mustard family of medications.[2][3] It works by disrupting the duplication of DNA and the creation of RNA.[2]
Ifosfamide was approved for medical use in the United States in 1987.[2] It is on the World Health Organization's List of Essential Medicines.[4]